News about Global Pharma

CorestemChemon Partners with ATG Lifetech to Expand Global CRO Footprint

CorestemChemon Partners with ATG Lifetech to Expand Global CRO Footprint

CorestemChemon, a South Korea–based GLP-certified preclinical CRO, has partnered with ATG Lifetech to co-develop advanced transcriptome and organoid-based platforms, aiming to deliver precision-driven, next-gen preclinical solutions to global pharma and biotech clients.

Global Pharma | 21/07/2025 | By Mrinmoy Dey 131

Alembic Pharma Appoints Dr. Sachin Ghosalkar as Senior VP - SCM and Operations

Alembic Pharma Appoints Dr. Sachin Ghosalkar as Senior VP - SCM and Operations

Alembic Pharmaceuticals Ltd. has announced the appointment of Dr. Sachin Ghosalkar as Senior Vice President – Supply Chain Management (SCM) and Operations, designated as Senior Management Personnel of the company.

Global Pharma | 21/07/2025 | By Dineshwori 359

Moderna Halts Plans for mRNA Manufacturing Facility in Japan Amid Business Uncertainty

Moderna Halts Plans for mRNA Manufacturing Facility in Japan Amid Business Uncertainty

The US-based vaccine maker announced on Friday that it would not proceed with its project at the Shonan Health Innovation Park (iPark) in Fujisawa, Kanagawa Prefecture. The decision follows “careful consideration given the current business environment,” according to a statement from Moderna’s Japan unit.

Global Pharma | 21/07/2025 | By Darshana 360

FDA Drug Approvals Fall in 2024, But Small Pharma Fuels Innovation Surge

FDA Drug Approvals Fall in 2024, But Small Pharma Fuels Innovation Surge

The US Food and Drug Administration (FDA) approved 127 innovator and biosimilar drugs in 2024, marking a decline from the 149 approvals recorded in 2023, according to a report by leading data and analytics firm GlobalData.

Global Pharma | 19/07/2025 | By Dineshwori 476

India's Rising Role in the Global Pharma Supply Chain

India's Rising Role in the Global Pharma Supply Chain

One of the key drivers behind India’s growing role is its expansive manufacturing infrastructure. The country is home to more than 3,000 pharmaceutical companies and over 10,500 manufacturing units.

Global Pharma | 19/07/2025 | By Darshana 277

Pharma Leaders Back UK Life Sciences Strategy, But ABPI Warns of Medicines Investment Gap

Pharma Leaders Back UK Life Sciences Strategy, But ABPI Warns of Medicines Investment Gap

Pharmaceutical and medical technology leaders, including GSK, Sandoz, Accord Healthcare, Becton Dickinson, and Celltrion have welcomed the UK government’s new Life Sciences Sector Plan, recently unveiled as part of its flagship Industrial Strategy.

Global Pharma | 19/07/2025 | By Dineshwori 224

Mallinckrodt Secures Irish High Court Approval for Merger with Endo

Mallinckrodt Secures Irish High Court Approval for Merger with Endo

Mallinckrodt plc has announced that it has received the final ruling from the Irish High Court, clearing the way for its merger with Endo, Inc. to form a global, diversified therapeutics company.

Global Pharma | 19/07/2025 | By Mrinmoy Dey 225

Cipla Appoints BNP and Associates as Secretarial Auditors for Five-Year Term

Cipla Appoints BNP and Associates as Secretarial Auditors for Five-Year Term

Cipla Limited has appointed M/s BNP and Associates as its Secretarial Auditors for a five-year term, commencing from the conclusion of the company’s 89th Annual General Meeting (AGM) and continuing until the conclusion of the 94th AGM.

Global Pharma | 19/07/2025 | By Dineshwori 228

Oragenics, Sterling Pharma Solutions Ink Manufacturing Deal for Concussion Drug

Oragenics, Sterling Pharma Solutions Ink Manufacturing Deal for Concussion Drug

Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion.

Global Pharma | 18/07/2025 | By Dineshwori 256

Samsung Bioepis Partners with Harrow for US Commercialisation of Ophthalmology Biosimilars

Samsung Bioepis Partners with Harrow for US Commercialisation of Ophthalmology Biosimilars

Following the transition of commercial rights from Biogen back to Samsung Bioepis, Harrow will assume full responsibility for the commercialisation of both BYOOVIZ and OPUVIZ biosimilars in the US.

Global Pharma | 18/07/2025 | By Dineshwori 295

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members